Skip to main content
Smart Investors Daily
AM

NASDAQ · AMRX

Amneal Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$21.23

Down-$0.15 (-0.70%)

Updated Nov 17, 2026, 10:07 AM

SID Score

5.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.34B
P/E ratio
60.06
Dividend yield
0.00%
52-week range
$11.39 – $22.07
Volume
1.68M
Avg. volume
2.49M

Price performance · AMRX

AMRX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

AMRX closed at $21.23 after 21 trading sessions, up 9.66% for the selected period.

Last close
$21.23
Period change
+9.66%
Period low
$19.36
Period high
$21.71
Daily close
View OHLC price history
AMRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$21.47$21.60$21.10$21.231.68M
Nov 13, 2026$21.485$21.72$21.30$21.381.72M
Nov 12, 2026$21.71$22.0652$21.25$21.701.56M
Nov 11, 2026$21.47$22.005$21.44$21.712.47M
Nov 10, 2026$21.28$21.63$21.025$21.382.36M
Nov 9, 2026$20.45$21.365$20.29$21.282.63M
Nov 6, 2026$19.45$20.43$19.30$20.144.73M
Nov 5, 2026$20.04$20.48$19.385$19.454.95M
Nov 4, 2026$20.55$20.55$19.015$19.957.23M
Nov 3, 2026$19.93$20.8054$19.50$20.216.44M
Nov 2, 2026$21.53$21.6811$20.30$20.445.02M
Oct 30, 2026$21.51$21.68$21.27$21.512.77M
Oct 29, 2026$21.51$21.65$21.11$21.354.4M
Oct 28, 2026$21.325$21.675$21.07$21.143.31M
Oct 27, 2026$20.93$21.46$20.93$21.442.89M
Oct 26, 2026$20.63$21.14$20.5435$21.024.95M
Oct 23, 2026$20.45$20.49$19.9301$20.384.93M
Oct 22, 2026$20.32$20.579$20.205$20.486.04M
Oct 21, 2026$19.90$20.30$19.7302$20.204.66M
Oct 20, 2026$19.51$19.91$19.31$19.846.82M
Oct 19, 2026$19.10$19.445$18.95$19.362.1M

Latest AMRX news

The latest Smart Investors Daily articles mentioning AMRX.

AMRX research

Overview

Company profile and research snapshot.

Company profile

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.00
Implied upside
—
Analysts
—
AMRX recent ratings
DateFirmRatingTarget
Nov 5, 2026Leerink PartnersOutperform—
Nov 4, 2026JP MorganOverweight—
Oct 22, 2026JP MorganOverweight—
Sep 23, 2026OppenheimerOutperform—
Sep 17, 2026BarclaysOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.